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Abstract
 
Immune surveillance by cytotoxic lymphocytes against cancer has been postulated for decades,
but direct evidence for the role of cytotoxic lymphocytes in protecting against spontaneous
malignancy has been lacking. As the rejection of many experimental cancers by cytotoxic T
lymphocytes and natural killer cells is dependent on the pore-forming protein perforin (pfp),
 
we examined pfp-deficient mice for increased cancer susceptibility. Here we show that pfp-
deficient mice have a high incidence of malignancy in distinct lymphoid cell lineages (T, B,
NKT), indicating a specific requirement for pfp in protection against lymphomagenesis. The
susceptibility to lymphoma was accentuated by simultaneous lack of expression of the p53
gene, mutations in which also commonly predispose to human malignancies, including lym-
phoma. In contrast, the incidence and age of onset of sarcoma was unaffected in p53-deficient
mice. Pfp-deficient mice were at least 1,000-fold more susceptible to these lymphomas when
transplanted, compared with immunocompetent mice in which tumor rejection was controlled
by CD8
 
1
 
 T lymphocytes. This study is the first that implicates direct cytotoxicity by lympho-
cytes in regulating lymphomagenesis.
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Introduction
 
Burnet first forwarded the concept of tumor immune sur-
veillance (1) and others, such as Thomas (2), have devel-
oped this idea. Since then, it has largely been assumed that
both innate (including NK cells) and acquired (including
CTLs) mechanisms may contribute to host antitumor im-
munity by destroying transformed cells or creating a local
environment that suppresses tumor growth. Although di-
rect cytotoxicity by NK cells and CTLs can be used as one
critical indicator of antitumor immunity in experimental
cancer models (3), a good correlation is not found in most
spontaneously occurring human cancers, or even in human
immunotherapy trials designed to stimulate antitumor cy-
totoxicity (4). Perforin (pfp),
 
 
 
exclusively expressed by NK
cells and CTLs (5, 6), is essential for inducing tumor cell
apoptosis in vitro (7, 8) and pfp-deficient mice show an in-
crease in the growth (9, 10) and metastasis (11) of experi-
mental tumors. Nevertheless, evidence for a role of killer
cell cytotoxicity in surveillance against spontaneous cellular
transformation is lacking. In addition, none of the tumor
models used to study antitumor cytotoxicity have accu-
rately mimicked the clinical setting where tumors arise spo-
radically after clonal expansion of a single transformed cell.
 
We chose to address this issue by examining whether
pfp-deficient mice have an abnormal incidence or an altered
pathological spectrum of cancer over their life-span. This
approach presented a potential problem, as it had previously
been reported that pfp-deficient mice up to 12 mo of age
are not abnormally prone to malignancy (9), indicating that
any increased susceptibility to cancer would take consider-
able time to become apparent. Mutations of p53, a key reg-
ulator of apoptosis and cell-cycle arrest in response to DNA
damage (12), are found in approximately half of all human
cancers (13, 14), and inherited mutations exemplified by Li-
Fraumeni syndrome are strongly associated with increased
susceptibility to epithelial, lymphoid and connective tissue
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malignancies (15). We thus elected to examine whether tu-
morigenesis would be accelerated in tumor-prone p53-defi-
cient mice (16, 17) that also lacked pfp expression.
 
Materials and Methods
 
Mice.
 
C57BL/6 
 
3
 
 129/Sv pfp-deficient mice (18; courtesy
of Dr. William Clark, University of California, Los Angeles, CA)
were backcrossed five generations to C57BL/6 mice (purchased
from the Walter and Eliza Hall Institute for Medical Research,
Parkville, Australia). These mice were then bred to C57BL/6
(B6).p53
 
1/2
 
 mice (backcross
 
 n 
 
5 
 
15) obtained from Dr. Alan
Harris (Walter and Eliza Hall Institute for Medical Research) to
generate mice that were heterozygous for both the perforin and
p53 alleles.
 
Experimental Carcinogenesis.
 
A total of 48 pfp
 
1/2
 
p53
 
1/2
 
founder parent pairs were used to generate progeny that ex-
pressed all possible combinations of alleles (9 genotypes). Each
genotype comprised 
 
z
 
50% male and 50% female mice. All mice
were bred and maintained in a single clean room of the Austin
Research Institute Biological Research Laboratories. Soon after
birth, the genotype of each mouse was determined from genomic
DNA (sampled by tail clipping) using both Southern blot analysis
and PCR. The results were recorded and the mice were then
raised anonymously in their original litters for the length of the
experiment. The PCR method for screening pfp used the follow-
ing oligomers: 5
 
9
 
-CGT GAG AGG TCA GCA TCC TTC-3
 
9
 
(sense primer in exon 2); 5
 
9
 
-TGG CCT AGG GTT CAC ATC
CAG-3
 
9
 
 (antisense primer in exon 2, downstream of the unique
SmaI site into which the neomycin resistance gene cassette was
inserted to disrupt the coding sequence); and 5
 
9
 
-ATA TTG GCT
GCA GGG TCG CTC-3
 
9
 
 (antisense primer within neomycin
resistance gene cassette). The screening of p53 used the following
oligomers: 5
 
9
 
-TTA TGA GCC ACC CGA GGT-3
 
9
 
; 5
 
9
 
-TAT
ACT CAG AGC CGG CCT-3
 
9
 
; and 5
 
9
 
-TCC TCG TGC TTT
ACG GTA TC-3
 
9
 
. All mice were routinely screened for viruses,
parasites, and other microbes and tested negative over the entire
course of the experiment. Mice within the study were monitored
for health and weighed twice weekly. Any mouse with an abnor-
mality (palpable mass, abdominal distension, weight loss 
 
.
 
10%,
or ruffled fur) was killed, its age was recorded, and a postmortem
was performed. Mean age of death 
 
6
 
 SEM was calculated and
the probability of significance was determined using a nonpara-
metric Mann-Whitney test. The significance of proportions of
tumors and in particular disseminated lymphomas was deter-
mined by a Fisher’s exact test.
 
Histopathology and Surface Phenotyping of Tumors.
 
A full au-
topsy was performed at death, and tumors (macroscopically de-
tected), spleen, liver, thymus, and lymph nodes were routinely
examined by histology after fixing these tissues in formalin and on
occasion also fresh freezing them. The preparation and staining of
sections for histology were carried out by the Department of Ana-
tomical Pathology, Austin and Repatriation Medical Centre. No
data from these analyses suggested to us that pfp
 
2/2
 
/p53 mutant
mice developed a spectrum of tumors that was distinct from that
typically reported and observed in corresponding pfp
 
1
 
/
 
1
 
/p53 mu-
tant mice (i.e., tumors were primarily sarcomas and lymphomas).
Lymphomas from B6.pfp
 
2/2
 
p53
 
1/2
 
 mice were also assessed for
surface phenotype by multiparameter flow cytometric analysis.
The following reagents were used: anti–
 
a/b
 
-TCR–FITC (H57-
597; PharMingen); anti–NK1.1-PE (PK136; PharMingen);
anti–CD4-FITC (CT4; Caltag Laboratories); anti–CD8
 
a
 
-APC
(53.6.7; PharMingen); anti–CD8
 
b
 
-biotin (53.5.8; PharMingen);
 
anti–CD11c-FITC (HL3; PharMingen); anti–B220-PE (RA3-
6B2; Caltag Laboratories); anti–Thy-1–PE (30-H12; PharMin-
gen); anti–CD45.2-FITC (104; PharMingen); anti–
 
g/d
 
-TCR–bio-
tin (clone GL3; PharMingen); anti–Mac-1–biotin (M170; Caltag
Laboratories); goat anti–mouse-Ig–FITC (Silenus Laboratories);
and anti–Streptavidin-tricolor (Caltag Laboratories). Anti-Fc re-
ceptor (2.4G2) was used to prevent nonspecific binding by mAb.
Staining was carried out in PBS with 5% FCS and 0.02% sodium
azide on ice. Fresh splenocytes from 6-wk-old B6 mice were al-
ways used as labeling controls. Analysis was carried out on a FACS-
calibur™ using CellQuest software (Becton Dickinson).
 
Tumor Transplantation Experiments.
 
Nine lymphomas were
transplanted directly from B6.pfp
 
2/2
 
p53
 
1/2
 
 or pfp
 
2/2
 
p53
 
1
 
/
 
1
 
mice into B6 and B6.pfp
 
2/2
 
 mice and subsequently maintained in
B6.pfp
 
2/2
 
 mice. Two of these, designated PN53H-1 (B220
 
1
 
H-2K
 
b
 
1
 
H-2D
 
b
 
1
 
Ig
 
1
 
) and PN53H-7 (CD8
 
a/b
 
1
 
B220
 
1
 
lin
 
2
 
H-2K
 
b
 
1
 
H-2D
 
b
 
1
 
), were randomly chosen to further investigate factors
regulating their growth in B6 mice. Groups of five B6 or
B6.pfp
 
2/2
 
 mice were injected intraperitoneally with increasing
numbers of lymphoma cells and observed daily for tumor growth
for 
 
.
 
100 d. Some groups of B6 mice were depleted of NK1.1
 
1
 
,
Thy-1
 
1
 
, or CD8
 
1
 
 cells in vivo, by treatment with 100 
 
m
 
g anti-
NK1.1 (PK136), anti–Thy-1 (T24/31.7) mAb, or anti-CD8 (53-
6.7) respectively, on days 
 
2
 
2 and 0 (day of i.p. tumor inocula-
tion) and weekly thereafter. This protocol has been demonstrated
to effectively deplete NK1.1
 
1
 
, Thy-1
 
1
 
, or CD8
 
1
 
 cells (11).
 
Results and Discussion
 
Mixed litters comprising the nine resulting genotypes of
pfp
 
1/2
 
p53
 
1/2
 
 intercrossed mice were monitored for tumor
development (Fig. 1). All the offspring were observed for
up to 2 yr, under standard (non-pathogen free) boarding
conditions.
 
Perforin-deficient Mice Develop Spontaneous Late Onset Lym-
phoma.
 
As previously reported (9), no pfp
 
2/2
 
p53
 
1
 
/
 
1
 
 mice
developed cancer before 12 mo of age. Soon thereafter,
however, these mice began to succumb to aggressive dis-
seminated lymphomas affecting the spleen, liver and lymph
nodes (between 436 and 635 d, mean age at time of death
[MA]
 
 5 
 
569 
 
6
 
 22 d). The difference in lymphoma inci-
dence in pfp
 
2/2
 
p53
 
1
 
/
 
1
 
 (10 out of 20) and pfp
 
1
 
/
 
1
 
p53
 
1
 
/
 
1
 
 (1
out of 16) was highly significant (
 
P
 
 5 
 
0.0091 Fisher’s exact
test; Fig. 1, A and D). As mice heterozygous for pfp expres-
sion (pfp
 
1/2
 
p53
 
1
 
/
 
1
 
) did not develop any lymphomas (0 out
of 20), 
 
,
 
3% (1 out of 36) of the mice expressing at least
one perforin allele succumbed to lymphoma. Given the
group sizes in our experiments, the collective incidence of
nonlymphatic malignancies in these groups of mice (3 out
of 56, comprising two sarcomas and one hepatoma) was
too low to evaluate whether pfp expression influenced sus-
ceptibility to other types of cancer.
 
p53 Deficiency Accentuates Lymphomagenesis.
 
The associ-
ation between pfp deficiency and susceptibility to lym-
phoma was strongly reiterated in p53
 
1/2
 
 mice, and the MA
was also hastened by 90 d compared with p53
 
1
 
/
 
1
 
 mice.
Pfp
 
2/2
 
p53
 
1/2
 
 mice typically developed lymphoma between
days 338 and 606 (MA 
 
5 
 
569 
 
6
 
 22 d vs. 479 
 
6
 
 22 d;
 
 P 
 
5
 
0.0264, Mann-Whitney). In agreement with Jacks et al.
(16), p53
 
1/2
 
 mice expressing wild-type pfp levels rarely de- 
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veloped spontaneous tumors before day 250, and 50% (15
out of 30) had developed tumors by day 650 (Fig. 1, B and
D). Strikingly, however, only 2 out of these 15 tumors
were disseminated lymphomas. Thus, both the incidence of
tumors (23 out of 27;
 
 P 
 
5 
 
0.0058, Fisher’s exact test) and
the proportion of lymphomas (16 out of 23;
 
 P 
 
5 
 
0.0019)
were dramatically increased in pfp
 
2/2
 
p53
 
1/2
 
 mice. By con-
trast, the incidence and age of onset of sarcomas or other
tumors were not significantly different between the two
groups. Overall, we view the effect of p53 deficiency on
lymphomagenesis as an amplification of the effects of failed
pfp-dependent immune surveillance against transformed
lymphocytes. Although additional p53 heterozygosity
clearly resulted in an earlier onset of lymphoma in pfp-defi-
cient mice, the incidence of lymphoma was unaffected (16
out of 27 vs. 10 out of 20, respectively;
 
 P 
 
5 
 
0.2587).
Therefore pfp, and not p53, plays an indispensable role
against the development of lymphoma in otherwise normal
inbred mice.
Also consistent with previous reports (16, 17), all pfp
 
1
 
/
 
1
 
p53
 
2/2
 
 mice developed a spectrum of tumors, predomi-
nantly thymic lymphomas, disseminated lymphomas, or
sarcomas arising in soft tissue, bone, or blood vessel endo-
 
thelium by day 300 (MA 
 
6
 
 SE 
 
5 
 
172 
 
6
 
 8 d,
 
 n 5 34; Fig. 1
C). The distribution of tumor types was indistinguishable
in pfp2/2p532/2 mice, and the MA of this group was not
significantly reduced (151 6 9 d; P 5 0.1128, Mann-
Whitney). However, when tumor type was taken into ac-
count, it was apparent that the MA was once again signifi-
cantly reduced for disseminated lymphomas (144 6 15 vs.
197 6 15; P 5 0.0328), but interestingly, not for sarcomas
(147 6 16 vs. 154 6 12 d; P . 0.05) or thymic lympho-
mas (150 6 14 vs. 160 6 18 days; P . 0.05). Therefore,
within the limits of these group sizes, pfp did not appear to
control the development of spontaneous thymic lympho-
mas in p53 mutant mice. This data may be consistent with
the fact that mature effector T cells do not typically recir-
culate through the thymus, and whether immunosurveil-
lance of thymic lymphoid cells fails to occur by other
means remains to be demonstrated. To illustrate the signifi-
cance of the earlier onset of disseminated lymphomas in
pfp2/2p532/2 mice, the reduction in MA was comparable
to that observed by others when p532/2 mice received
added oncogenic stimuli (g-irradiation as neonates [19] or a
coincident deficiency of one Rb [20] or scid [21] allele), or
immune compromise due to deficiency of IFN-gR expres-
Figure 1. Perforin  protects
mice from spontaneous lympho-
mas. The appearance of tumors
was recorded in mice derived
from a pfp1/2p531/2 intercross.
Groups of mice (n 5 16–34)
were evaluated on a weekly basis
and when moribund, tumor type
(h, thymic lymphoma; j, dis-
seminated lymphoma; m, sar-
coma;  s, other tumors) recorded
against the age at time of death/
autopsy (in days). The perforin
genotype (pfp2/2, pfp1/2, or
pfp1/1) is also displayed on the
x-axis. (A) p531/1, (B) p531/2,
or (C) p532/2. The MA of p532/2
mice developing disseminated
lymphoma is depicted by the
crossbar in C. All p532/2 mice
studied developed tumors and
the numbers of p531/2 and p531/1
mice developing lymphomas are
shown in parentheses. In D, the
percentage of pfp2/2 and pfp1/1
mice free of disseminated lym-
phoma (from A and B) are plot-
ted against their age at time of
death in days, and P values
(Fisher’s exact test) comparing
the proportions of disseminated
lymphoma between pfp2/2 and
pfp1/1 mice are indicated.758 Perforin Controls Spontaneous Lymphoma
sion (22). In contrast to IFN-gR2/2p532/2 mice in which
increased carcinogenesis might be due to a lack of any of
the pleiotropic effects of IFN-g (23), our study with pfp-
deficient mice represents the first in which increased cancer
susceptibility can be related precisely to a lack of cytolytic
lymphocyte effector function.
There was no difference in tumor histology or spread of
lymphoma in pfp1/1 and pfp2/2 mice (data not shown).
Similarly, the proportions of sarcomas that were undiffer-
entiated or arising in blood vessels or bone in pfp2/2p531/2
and pfp1/1p531/2 mice were unaltered. It was noted that
pfp1/2p531/2 and pfp1/2p532/2 mice displayed a tumor in-
cidence, spectrum and onset that was not statistically differ-
ent from pfp1/1 mice sharing the same p53 genotype (data
not shown). As pfp1/2 mice may have only half the normal
level of pfp protein expression, we were also interested to
find that pfp1/2p532/2 mice had an intermediate onset of
lymphoma (174 6 15 d) compared with pfp1/1p532/2
(197 6 15 d) or pfp2/2p532/2 (144 6 15 d). Although this
finding could be consistent with a gene dose effect in lym-
phoma surveillance, the MA for pfp heterozygotes was not
significantly different from either pfp1/1p532/2 or pfp2/2
p532/2 mice (P . 0.2, Mann-Whitney). Furthermore, no
evidence of a pfp gene dose effect was seen with either the
p531/1 or p531/2 cohorts.
A Variety of Lymphoma Phenotypes. To further charac-
terize the disseminated lymphomas arising in pfp2/2p531/2
and pfp2/2p531/1 mice, a total of 11 tumors were passaged
intraperitoneally in B6.pfp2/2 and/or scid mice. Of these,
nine were successfully passaged, and eight were analyzed by
flow cytometry. Unlike previously described lymphomas in
p531/2 or p532/2 mice (reference 21 and our unpublished
data), which were predominantly of T cell origin, the tumors
arising in pfp2/2p531/2 and pfp2/2p531/1 mice included
three of B cell origin (B2201sIg1CD42CD82TCR2), three
lymphomas of uncertain lineage (CD451lin2CD8a/b1/2
B2201/2), one T cell lymphoma (CD8a/b1TCR-a/b1
B2202CD42), and one NK T cell lymphoma (NK1.11
TCR-a/b1B2201CD42CD82). All lymphomas examined
were MHC class I1 (H-2Kb and H-2Db) and CD1d1 and
thus potentially capable of presenting tumor antigen to
MHC class I–restricted CTLs.
CTL-mediated Rejection of Transplanted Lymphomas. To
establish the malignancy of these tumors and that immune
surveillance had failed in pfp-deficient mice, lymphomas
were transplanted into wild-type B6 or B6.pfp2/2 mice.
Two representative experiments of the nine lymphomas
that were inoculated are depicted in Fig. 2. Surprisingly, as
few as 103 lymphoma cells (PN53H-1, B2201H-2Kb1
H-2Db1Ig1) killed all B6.pfp2/2 mice or B6 mice de-
pleted of Thy-11 or CD81 cells within 60–80 d of i.p. in-
oculation (Fig. 2 A). Similarly, only 103 PN53H-7 lym-
phoma (CD8a/b1B2201lin2H-2Kb1H-2Db1) cells killed
all B6.pfp2/2 mice or B6 mice depleted of Thy-11 or
CD81 cells within 25–55 d of i.p. inoculation (Fig. 2 B).
When transplanted, these tumors (and the other lympho-
mas studied) displayed a pattern of organ infiltration similar
to that originally observed. In contrast, up to 106 PN53H-1
or PN53H-7 lymphoma cells were effectively cleared in
untreated or anti-NK1.1–treated B6 mice (Fig. 2), and the
majority of B6 mice receiving even greater doses of inocu-
lum (.107) did not develop tumor (data not shown). Inter-
estingly, one B6 mouse that did succumb to higher doses of
PN53H-1 cells developed a lymphoma that appeared to
have escaped immune detection by losing expression of
MHC class I Kb (Db1Kb2). Upon subsequent transfer, this
lymphoma grew in both B6 and B6.pfp2/2 mice at doses
from 105–107 cells (data not shown). Despite the fact that
all lymphomas arising in pfp2/2p531/2 mice were effi-
ciently killed by IL-2–activated NK cells from B6 (data not
shown), tumor growth occurred with 104–105 times fewer
cells in B6.pfp2/2 mice, and T cells, not NK cells, were re-
sponsible for lymphoma rejection. To eliminate any possi-
bility that minor 129 alloantigens potentially expressed by
the lymphomas may have accounted for their rapid rejec-
tion in B6 mice, five of the lymphomas (including
PN53H-1) were transplanted (107 cells) into (B6 3 129)F1
mice. The similar rejection of these lymphoma cells in B6
and (B6 3 129)F1 mice confirmed that tumor antigens, not
alloantigens, were responsible for these rejection responses.
Figure 2. Spontaneous lymphomas arising in pfp2/2p531/2 mice are
malignant, immunogenic, and rejected by CD81 T cells. Elimination of
lymphomas transplanted directly intraperitoneally (102–106 cells in 0.2 ml
PBS, as indicated) into untreated B6 or B6.pfp2/2 mice or B6 mice (5/
group) depleted of Thy-11, NK1.11, or CD81 cells using mAb (24).
Each symbol depicts an individual mouse. A, PN53H-1; B, PN53H-7.759 Smyth et al. Brief Definitive Report
In conclusion, our collective data strongly indicated
that cytotoxic lymphocyte pfp offers protection from dis-
seminated lymphoma. The absence of pfp led to increased
lymphomagenesis in several distinct cell lineages and p53
mutation enhanced spontaneous tumor formation. Trans-
plantation of these lymphomas into wild-type and lym-
phocyte subset–depleted mice revealed that tumor rejec-
tion was dependent upon CD81 T cells. Importantly, this
is the first study to demonstrate that lymphocyte-mediated
cytotoxicity plays an important role in promoting host re-
sistance to spontaneous tumor formation. As such, it pro-
vides encouragement that efforts to promote CTL cyto-
toxicity directed at tumors have merit.
Notwithstanding the clear differences seen in lymphoma
incidence, many additional questions are raised by our
studies. The lymphomas arising in pfp-deficient mice ap-
peared to be controlled by CD81 T cells, yet clearly other
innate cell types, such as NK and NKT cells, express pfp
and control tumor development and metastasis (11, 24). In-
terestingly, the lymphomas arising in the absence of appre-
ciable NK cytotoxicity apparently experience no selective
pressure to lose MHC class I expression when pfp is also
absent in host T cells. Given the role of CD81 T cells dem-
onstrated herein, it is curious that the reported rates of
spontaneous tumor development in nu/nu (T cell–defi-
cient) and scid/scid (B and T cell–deficient) mice are very
low (25, 26). Interestingly, scid/NOD mice (with defective
NK cell cytotoxicity) have a high incidence of thymoma
(27), and thus innate effector cells using pfp may help
maintain immune surveillance despite the lack of functional
T cells. Although the bg/bg mutation in NK cell degranula-
tion, predisposes this natural mutant mouse to disseminated
malignant lymphoma and increased metastasis (28, 29), the
relative importance of NK or NKT cells in tumor immune
surveillance will be better determined in mice exclusively
deficient of each cell type.
The genetic background of mice and their housing con-
ditions may be important factors that determine tumor in-
cidence and type. We are currently assessing pfp deficiency
in BALB/c mice and another strain of gene-targeted
C57BL/6 mice (10) in the same clean facility. It has been
well documented that a large proliferative expansion and
persistence of antigen-reactive T and B cells and APCs oc-
curs in pfp-deficient mice challenged with lymphocytic
choriomeningitis virus (LCMV). These mice also experi-
ence reductions in bone marrow hematopoietic precursor
cells, probably due to enhanced hemophagocytosis (10, 30,
31). This condition bears a striking resemblance to the hu-
man autosomal recessive immunodeficiency, familial he-
mophagocytic lymphohistiocytosis (FHL), which presents
in infancy with hepatosplenomegaly due to a pronounced
histiocytic infiltrate, hemophagocytosis, and immune sup-
pression characterized by reduced or absent NK cell activ-
ity (32). Some of these patients have been shown to lack
perforin expression, due to inherited mutations in the per-
forin gene (32). Although the mice were not exposed to
LCMV, nor developed histiocytic infiltrates, in this study,
it is possible that other microorganisms might provide anti-
genic stimulation also leading to lymphoproliferation, ex-
tended cell survival, and an increased pool of cells vulnera-
ble to oncogenesis in pfp2/2 mice. Thus, the increased
lymphoma incidence associated with pfp-deficiency might
still have its genesis both in an increased number of prema-
lignant cells and the absence of the cytotoxic mechanism
that normally eliminates them. Alternatively, murine lym-
phomas are often associated with reactivation of endoge-
nous retroviruses during senescence, and thus the antigenic
targets of the CTLs controlling these lymphomas might be
viral. It is harder to propose this same etiology to the lym-
phomas arising in much younger p532/2 mice, implying
that direct perforin-mediated cytolysis normally eliminates
these lymphomas regardless of their genesis.
Given that pfp is also critical in protection from methyl-
cholanthrene-induced fibrosarcoma (9, 24), we are left to
ponder why the absence of pfp does not additionally sensi-
tize p531/2 mice to spontaneous sarcoma. Clearly, more
needs to be understood about the influence different onco-
genic hits have on shaping the host immune response to
different cell types, and the effector mechanism(s) that are
subsequently mobilized. Although the oncogenic events
underlying the development of spontaneous lymphomas in
pfp2/2p531/1 and pfp2/2p531/2 mice remain to be deter-
mined at the molecular level, it is clear that these tumors
present target structure(s) that can be recognized by CTLs,
and pfp-dependent granule-mediated cytolysis is protec-
tive. Future studies to further evaluate the potential role of
pfp in controlling other lymphoid malignancies and sponta-
neous tumors arising in nonlymphoid tissues will be of
great interest.
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